Fluoroquinolone resistance among Salmonella enterica serovar Paratyphi A in Pondicherry [2]

Indian Journal of Medical Research

Volumn 124, Issue , 2006, Pages 585-587

  Harish, B N ^a   Menezes, G A ^a   Sarangapani, K ^b   Parija, S C ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b Government General Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTISERUM; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOHEXANE; GATIFLOXACIN; NALIDIXIC ACID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIGEN ANTIBODY REACTION; BLOOD CULTURE; DRUG TREATMENT FAILURE; HUMAN; LABORATORY TEST; LETTER; MAJOR CLINICAL STUDY; NONHUMAN; SALMONELLA PARATYPHI; SALMONELLA TYPHI; SCREENING TEST; TYPHOID FEVER;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; SALMONELLA PARATYPHI A;

EID: 33846469350     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Letter

References (15)

1. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82: 346-53.
2. Sood S, Kapil A, Das N, Das BK, Goel V, Seth P. Paratyphoid fever in India: an emerging problem. Emerg Infect Dis 1999; 5: 483-4.
3. Chandel DS, Chaudhry R, Dhawan B, Pandey A, Dey AB. Drug resistant Salmonella enterica serovar paratyphi A in India. Emerg Infect Dis 2000; 6: 420-1.
4. Harish BN, Madhulika U, Parija SC. Isolated high-level ciprofloxacin in Salmonella enterica subsp. enterica serovar paratyphi A. J Med Microbiol 2004; 53: 819.
5. Adachi T, Sagara H, Hirose K, Watanabe H. Fluoroquinolone resistant Salmonella paratyphi A. Emerg Infect Dis 2005; 11: 172-4.
6. Collee JG, Miles RS, Watt B. Tests for the identification of bacteria. In: Collee JG, Fraser AG, Marmion BP, Simmons A, editors, Mackie & McCartney practical medical microbiology. 14th ed. London: Churchill Livingstone; 1996 p. 131-49.
7. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized angle disk method. Am J Clin Pathol 1996; 45: 493-6.
8. Clinical and Laboratory Standards Institute 2005. Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement M 100-S15 Clinical and Laboratory Institute, Wayne Pa.
9. Threlfall EJ, Ward LR. Decreased susceptibility to ciprofloxacin in Salmonella typhi, United Kingdom. Emerg Infect Dis 2001; 7: 448-50.
10. Hakanen A, Kotilainen P, Jalava J, Scitonen A, Huoveinen P. Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. J Clin Microbiol 1999; 37: 3572-7.
11. Liebana E, Clouting C, Cassar CA, Randall LP, Walker RA, Threlfall EJ, et al. Comparison of gyrA mutations, cyclohexane resistance and the presence of class I integrous in Salmonella enterica from farm animals in England and Wales. J Clin Microbiol 2002; 40: 1481-6.
12. Asako H, Kobayashi K, Aono R. Organic solvent tolerance of Escherichia coli independent of OmpF levels in the membrane. Appl Environ Microbiol 1999; 65: 294-6.
13. Ochiai RL, Wang X, von Siedlien L, Yang J, Bhutta ZA, Bhattacharya SK, et al. Salmonella paratyphi A rates, Asia. Emerg Infect Dis 2005; 11: 1764-6.
14. Sanders CC. Mechanisms responsible for cross resistance and dichotomous resistance among quinolones. Clin Infect Dis 2001; 32: 51-8.
15. Satheesh N, Madhulika U, Keith T, Parija SC, Carol C, John W, et al. Molecular analysis of fluoroquinolone- resistant S. paratyphi A isolate, India. Emerg Infect Dis 2006; 12: 3.